Delivery Order SPE2DR25D3014-SPE2DR26FP1FV
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,128.45 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) under a firm fixed price contract. The award, issued on June 2, 2025, with an ultimate completion date of June 3, 2025, represents a competitively awarded, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this delivery order from...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $61,503.38 on November 24, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens in 3mL quantities. This is a firm fixed-price, non-set-aside contract with a completion date of November 25, 2025, and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) with a ceiling value of $10,555.27. This firm fixed-price delivery order, which is scheduled for completion by November 4, 2025, represents a competitive award with no set-aside designation. The award was fulfilled by AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, the company's headquarters and primary...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $117,341.00 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a firm fixed price and an ultimate completion date of June 30, 2025. This non-competitive delivery order, issued on June 27, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $36,663.92 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) on September 25, 2025, with completion scheduled for September 26, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,376.44 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) on July 23, 2025, with completion targeted for July 24, 2025. This firm fixed price delivery order, which carries no set-aside designation, represents a competitively awarded procurement fulfilling federal pharmaceutical supply requirements. The contract will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $35,650.81 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) on December 9, 2025, with an ultimate completion date of December 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order valued at $2,523.08 to AmerisourceBergen Drug Corp for Ozempic 0.25-0.5 mg/dose pens (3ml) on December 3, 2025, with an ultimate completion date of December 4, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $4,465.02 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) on December 10, 2025, with a completion date of December 11, 2025. The contract was awarded on a non-competitive, firm fixed-price basis and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is listed as AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,227.31 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with an ultimate completion date of November 21, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite...
- SPE2DR25D3014Indefinite Delivery Contract
- SPE2DR25D3014-SPE2DR26FP1FVDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,106.55 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) under a firm fixed-price contract. The award, issued on December 8, 2025, with an ultimate completion date of December 9, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's existing indefinite delivery contract with DLA. The pharmaceutical supplies will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen Drug Corp's comprehensive DLA Troop Support Medical indefinite delivery contract (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen maintains an extensive portfolio supplying brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains to support military and veteran healthcare systems. The delivery of Ozempic, a diabetes medication, aligns with the company's established capabilities in providing specialized pharmaceutical products to federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Loading... | ||||